Eli Lilly has increased its 2025 guidance and reported strong second-quarter earnings, driven by high demand for its blockbuster weight loss and diabetes medications. The company raised its sales forecast to $60 billion to $62 billion, up from a previous outlook of $58 billion to $61 billion.
The pharmaceutical giant’s experimental obesity pill, orforglipron, also showed promising results in late-stage trial data, with the highest dose helping patients lose over 12% of their body weight. However, this news sent Eli Lilly’s shares down 12% in premarket trading on Thursday.
Mounjaro and Zepbound, two diabetes treatments from Eli Lilly, topped expectations for the second quarter, generating $5.2 billion and $3.38 billion in revenue respectively. This represents a 68% increase in Mounjaro sales and a 172% surge in Zepbound sales compared to the same period last year.
Eli Lilly’s CEO, David Ricks, expressed confidence in the company’s future prospects, citing strong growth on the back half of the year. He also highlighted the potential of Tirzepatide, which is Mounjaro and Zepbound, becoming the bestselling drug in its third year in the market.
The company’s results come as it prepares for levies on pharmaceuticals imported into the US and faces pressure to lower drug prices in the country. Despite this, Eli Lilly remains optimistic about its future prospects.
Source: https://www.cnbc.com/2025/08/07/eli-lilly-lly-q2-2025-earnings-report.html